CAR-T 세포치료 시장 : 약제 적응별, 적응증별, 최종사용자별, 지역별, 동향 분석, 경쟁 구도, 예측(2019-2030년)

Global CAR-T Cell Therapy Market Zooms 6.2X to Touch Whopping USD 57 Billion by 2030

Global CAR-T Cell Therapy Market is thriving due to increasing prevalence of cancer, a spurring demand for targeted therapies, and rapid adoption of technological advancements.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global CAR-T Cell Therapy Market size by value at USD 9.11 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global CAR-T Cell Therapy Market size to expand at a robust CAGR of 30.20% reaching a value of USD 56.80 billion in 2030. Global CAR-T Cell Therapy Market is driven by several key factors, including the increasing prevalence of cancer necessitates innovative treatments, boosting demand for CAR-T therapies. Advancements in CAR-T technology enhance treatment efficacy and safety. Growing demand for targeted and personalized therapies further propels market growth. Additionally, rising clinical trial activities and supportive regulatory frameworks encourage research and development, fostering market expansion.

Opportunity - Expansion into other Indications

Global CAR-T Cell Therapy Market is growing with the expansion of new regulations. Initially focused on leukemia, CAR-T therapies are now being investigated for solid tumors and other diseases. Wide access enables patients to access and drives the market. Ongoing research and clinical trials are aimed at increasing the efficacy of CAR-T therapies for the conditions, driving market expansion.

Impact of Escalating Geopolitical Tensions on Global CAR-T Cell Therapy Market

Increasing geopolitical tensions could impact Global CAR-T Cell Therapy Market by disrupting supply chains and increasing input costs. Trade restrictions and political and economic instabilities could delay production and distribution. These challenges are forcing manufacturers to seek new sources and change processes, potentially increasing prices for consumers and affecting market growth.

Yescarta Holds Major Share of Global CAR-T Cell Therapy Market

The Axicabtagene Ciloleucel (Yescarta) segment accounts for the largest market share of Global CAR-T Cell Therapy Market by drug indication, due to its high efficacy in treating certain types of blood cancers, particularly diffuse large B-cell lymphoma (DLBCL). Yescarta's success in clinical trials and its widespread adoption in various regions contribute to its leading position in the market. The other major drug indication segments in Global CAR-T Cell Therapy Market include Brexucabtagene Autoleucel (Tecartus), Ciltacabtagene Autoleucel (Carvykti), Idecabtagene Vicleucel (Abecma), Lisocabtagene Maraleucel (Breyanzi), and Tisagenlecleucel (Kymriah).

Competitive Landscape

Global CAR-T Cell Therapy Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Bristol-Myers Squibb, Sorrento Therapeutics, Inc., Celgene Corporation, Merck & Co., Inc., Novartis AG, Celyad Oncology, Juno Therapeutics, Inc., Autolus Therapeutics, Cellectis, Miltenyi Biotech, Intellia Therapeutics, and Pfizer, Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global CAR-T Cell Therapy Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global CAR-T Cell Therapy Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technological trends in Global CAR-T Cell Therapy Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the Market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global CAR-T Cell Therapy Market Insights

• 3.1. End User Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Rising prevalence of cancer
    • 3.2.1.2. Continuous advancements in cell engineering and genetic modification techniques
    • 3.2.1.3. Favorable regulatory landscape: for CAR-T cell therapy
    • 3.2.1.4. Growing interest from pharmaceutical companies, biotech firms, and investors
  • 3.2.2. Restraints
    • 3.2.2.1. High costs of CAR-T cell therapy
    • 3.2.2.2. Limited availability and access to CAR-T cell therapy is often restricted to a limited number of patients.
    • 3.2.2.3. Potential side effects associated with CAR-T cell therapy
  • 3.2.3. Opportunities
    • 3.2.3.1. Expansion into new indications
    • 3.2.3.2. Combining CAR-T cell therapy with other treatments
    • 3.2.3.3. Advancements in genomics and personalized medicine
  • 3.2.4. Challenges
    • 3.2.4.1. Manufacturing challenges associated with the production of CAR-T cell therapies
    • 3.2.4.2. Ensuring adequate reimbursement for CAR-T cell therapy
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global CAR-T Cell Therapy Market: Marketing Strategies

5. Global CAR-T Cell Therapy Market: Pricing Analysis

6. Global CAR-T Cell Therapy Market: Geography Analysis

• 6.1. Global CAR-T Cell Therapy Market, Geographical Analysis, 2023
• 6.2. Global CAR-T Cell Therapy, Market Attractiveness Analysis, 2024-2030

7. Global CAR-T Cell Therapy Market Overview

• 7.1. Market Size & Forecast, 2019-2030
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Indication
    • 7.2.1.1. Axicabtagene Ciloleucel (Yescarta)
    • 7.2.1.2. Brexucabtagene Autoleucel (Tecartus)
    • 7.2.1.3. Ciltacabtagene Autoleucel (Carvykti)
    • 7.2.1.4. Idecabtagene Vicleucel (Abecma)
    • 7.2.1.5. Lisocabtagene Maraleucel (Breyanzi)
    • 7.2.1.6. Tisagenlecleucel (Kymriah)
    • 7.2.1.7. Others
  • 7.2.2. By Indication
    • 7.2.2.1. Acute Lymphoblastic Leukemia
    • 7.2.2.2. Non-Hodgkin Lymphoma
    • 7.2.2.3. Multiple Myeloma
  • 7.2.3. By End User
    • 7.2.3.1. Hospitals
    • 7.2.3.2. Oncology Treatment Centers
  • 7.2.4. By Region
    • 7.2.4.1. North America
    • 7.2.4.2. Europe
    • 7.2.4.3. Asia Pacific (APAC)
    • 7.2.4.4. Latin America (LATAM)
    • 7.2.4.5. Middle East and Africa (MEA)

8. North America CAR-T Cell Therapy Market

• 8.1. Market Size & Forecast, 2019-2030
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Indication
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
    • 8.2.4.1. United States
    • 8.2.4.1.1. By Drug Indication
    • 8.2.4.1.2. By Indication
    • 8.2.4.1.3. By End User
    • 8.2.4.2. Canada
    • 8.2.4.2.1. By Drug Indication
    • 8.2.4.2.2. By Indication
    • 8.2.4.2.3. By End User

9. Europe CAR-T Cell Therapy Market

• 9.1. Market Size & Forecast, 2019-2030
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Indication
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
    • 9.2.4.1. Germany
    • 9.2.4.1.1. By Drug Indication
    • 9.2.4.1.2. By Indication
    • 9.2.4.1.3. By End User
    • 9.2.4.2. United Kingdom
    • 9.2.4.2.1. By Drug Indication
    • 9.2.4.2.2. By Indication
    • 9.2.4.2.3. By End User
    • 9.2.4.3. Italy
    • 9.2.4.3.1. By Drug Indication
    • 9.2.4.3.2. By Indication
    • 9.2.4.3.3. By End User
    • 9.2.4.4. France
    • 9.2.4.4.1. By Drug Indication
    • 9.2.4.4.2. By Indication
    • 9.2.4.4.3. By End User
    • 9.2.4.5. Spain
    • 9.2.4.5.1. By Drug Indication
    • 9.2.4.5.2. By Indication
    • 9.2.4.5.3. By End User
    • 9.2.4.6. Belgium
    • 9.2.4.6.1. By Drug Indication
    • 9.2.4.6.2. By Indication
    • 9.2.4.6.3. By End User
    • 9.2.4.7. Russia
    • 9.2.4.7.1. By Drug Indication
    • 9.2.4.7.2. By Indication
    • 9.2.4.7.3. By End User
    • 9.2.4.8. The Netherlands
    • 9.2.4.8.1. By Drug Indication
    • 9.2.4.8.2. By Indication
    • 9.2.4.8.3. By End User
    • 9.2.4.9. Rest of Europe
    • 9.2.4.9.1. By Drug Indication
    • 9.2.4.9.2. By Indication
    • 9.2.4.9.3. By End User

10. Asia Pacific CAR-T Cell Therapy Market

• 10.1. Market Size & Forecast, 2019-2030
  • 10.1.1. By Value (USD Billion)
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Indication
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
    • 10.2.4.1. China
    • 10.2.4.1.1. By Drug Indication
    • 10.2.4.1.2. By Indication
    • 10.2.4.1.3. By End User
    • 10.2.4.2. India
    • 10.2.4.2.1. By Drug Indication
    • 10.2.4.2.2. By Indication
    • 10.2.4.2.3. By End User
    • 10.2.4.3. Japan
    • 10.2.4.3.1. By Drug Indication
    • 10.2.4.3.2. By Indication
    • 10.2.4.3.3. By End User
    • 10.2.4.4. South Korea
    • 10.2.4.4.1. By Drug Indication
    • 10.2.4.4.2. By Indication
    • 10.2.4.4.3. By End User
    • 10.2.4.5. Australia & New Zealand
    • 10.2.4.5.1. By Drug Indication
    • 10.2.4.5.2. By Indication
    • 10.2.4.5.3. By End User
    • 10.2.4.6. Indonesia
    • 10.2.4.6.1. By Drug Indication
    • 10.2.4.6.2. By Indication
    • 10.2.4.6.3. By End User
    • 10.2.4.7. Malaysia
    • 10.2.4.7.1. By Drug Indication
    • 10.2.4.7.2. By Indication
    • 10.2.4.7.3. By End User
    • 10.2.4.8. Singapore
    • 10.2.4.8.1. By Drug Indication
    • 10.2.4.8.2. By Indication
    • 10.2.4.8.3. By End User
    • 10.2.4.9. Vietnam
    • 10.2.4.9.1. By Drug Indication
    • 10.2.4.9.2. By Indication
    • 10.2.4.9.3. By End User
    • 10.2.4.10. Rest of APAC
    • 10.2.4.10.1. By Drug Indication
    • 10.2.4.10.2. By Indication
    • 10.2.4.10.3. By End User

11. Latin America CAR-T Cell Therapy Market

• 11.1. Market Size & Forecast, 2019-2030
  • 11.1.1. By Value (USD Billion)
• 11.2. Market Share & Forecast
  • 11.2.1. By Drug Indication
  • 11.2.2. By Indication
  • 11.2.3. By End User
  • 11.2.4. By Country
    • 11.2.4.1. Brazil
    • 11.2.4.1.1. By Drug Indication
    • 11.2.4.1.2. By Indication
    • 11.2.4.1.3. By End User
    • 11.2.4.2. Mexico
    • 11.2.4.2.1. By Drug Indication
    • 11.2.4.2.2. By Indication
    • 11.2.4.2.3. By End User
    • 11.2.4.3. Argentina
    • 11.2.4.3.1. By Drug Indication
    • 11.2.4.3.2. By Indication
    • 11.2.4.3.3. By End User
    • 11.2.4.4. Peru
    • 11.2.4.4.1. By Drug Indication
    • 11.2.4.4.2. By Indication
    • 11.2.4.4.3. By End User
    • 11.2.4.5. Rest of LATAM
    • 11.2.4.5.1. By Drug Indication
    • 11.2.4.5.2. By Indication
    • 11.2.4.5.3. By End User

12. Middle East and Africa CAR-T Cell Therapy Market

• 12.1. Market Size & Forecast, 2019-2030
  • 12.1.1. By Value (USD Billion)
• 12.2. Market Share & Forecast
  • 12.2.1. By Drug Indication
  • 12.2.2. By Indication
  • 12.2.3. By End User
  • 12.2.4. By Country
    • 12.2.4.1. Saudi Arabia
    • 12.2.4.1.1. By Drug Indication
    • 12.2.4.1.2. By Indication
    • 12.2.4.1.3. By End User
    • 12.2.4.2. UAE
    • 12.2.4.2.1. By Drug Indication
    • 12.2.4.2.2. By Indication
    • 12.2.4.2.3. By End User
    • 12.2.4.3. Qatar
    • 12.2.4.3.1. By Drug Indication
    • 12.2.4.3.2. By Indication
    • 12.2.4.3.3. By End User
    • 12.2.4.4. Kuwait
    • 12.2.4.4.1. By Drug Indication
    • 12.2.4.4.2. By Indication
    • 12.2.4.4.3. By End User
    • 12.2.4.5. South Africa
    • 12.2.4.5.1. By Drug Indication
    • 12.2.4.5.2. By Indication
    • 12.2.4.5.3. By End User
    • 12.2.4.6. Nigeria
    • 12.2.4.6.1. By Drug Indication
    • 12.2.4.6.2. By Indication
    • 12.2.4.6.3. By End User
    • 12.2.4.7. Algeria
    • 12.2.4.7.1. By Drug Indication
    • 12.2.4.7.2. By Indication
    • 12.2.4.7.3. By End User
    • 12.2.4.8. Rest of MEA
    • 12.2.4.8.1. By Drug Indication
    • 12.2.4.8.2. By Indication
    • 12.2.4.8.3. By End User

13. Competitive Landscape

• 13.1. List of Key Players and Their Offerings
• 13.2. Global CAR-T Cell Therapy Company Market Share Analysis, 2023
• 13.3. Competitive Benchmarking, By Operating Parameters
• 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global CAR-T Cell Therapy Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

• 15.1. Bristol-Myers Squibb
• 15.2. Sorrento Therapeutics, Inc.
• 15.3. Celgene Corporation
• 15.4. Merck & Co., Inc.
• 15.5. Novartis AG
• 15.6. Celyad Oncology
• 15.7. Juno Therapeutics, Inc.
• 15.8. Autolus Therapeutics
• 15.9. Cellectis
• 15.10. Miltenyi Biotech
• 15.11. Intellia Therapeutics
• 15.12. Pfizer, Inc.
• 15.13. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

• 17.1. Qualitative Research
  • 17.1.1. Primary & Secondary Research
• 17.2. Quantitative Research
• 17.3. Market Breakdown & Data Triangulation
  • 17.3.1. Secondary Research
  • 17.3.2. Primary Research
• 17.4. Breakdown of Primary Research Respondents, By Region
• 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable